Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

7,852 total articles

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

Ascentage Pharma announced that six abstracts from clinical studies of its key drug candidates will be presented at the 2026 ASCO Annual Meeting, highlighting clinical progress in oncology drug development. Presentations include rapid oral presentations on Olverembatinib, Lisaftoclax, and Alrizomadlin, underlining the company's ongoing global clini…

Netskope Announces AI Guardrails Solution Powered by Google Cloud TPUs to Help Secure High-Performance AI Workflows at Scale

Netskope Announces AI Guardrails Solution Powered by Google Cloud TPUs to Help Secure High-Performance AI Workflows at Scale

Netskope announced an expanded partnership with Google Cloud to launch Netskope One AI Guardrails, a new solution integrating Google Cloud TPUs and Vertex AI to secure high-performance generative AI and autonomous agent workflows. This offering provides real-time safety checks, behavioral protections against AI-specific threats, and compliance supp…

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Kyverna Therapeutics reported positive primary analysis results from its registrational Phase 2 KYSA-8 trial of miv-cel, an autologous CD19-targeting CAR T-cell therapy, in patients with Stiff Person Syndrome (SPS). Miv-cel demonstrated statistically significant improvements in mobility and disability scores, eliminated the need for chronic immunot…

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Revolution Medicines presented updated Phase 1/2 clinical trial data for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The findings demonstrate manageable safety profiles and encouraging antitumor activity in both monotherapy and combination with chemotherapy, su…

Equus Announces Fourth Quarter Net Asset Value

Equus Announces Fourth Quarter Net Asset Value

Equus Total Return, Inc. reported a significant decrease in net asset value (NAV) per share to $1.19 at the end of Q4 2025 from $1.90 at the end of Q3 2025. This decline was primarily driven by a $12.35 million decrease in the fair value of its investment in Morgan E&P, Inc., linked to lower oil forward prices and elimination of some reserves. Conv…

Liberty Defense Announces Pricing of its U.S. Initial Public Offering

Liberty Defense Announces Pricing of its U.S. Initial Public Offering

Liberty Defense Holdings Ltd. has priced its initial public offering (IPO) in the United States, offering 3.67 million common shares at $4.50 per share and pre-funded warrants to raise about $20 million gross proceeds. The company's common shares will begin trading on the Nasdaq Capital Market on April 22, 2026 under ticker DETX, while delisting fr…

Greenlane Holdings Announces Upcoming Pre-Funded Warrant Conversion and Lock-Up of Strategic Advisor Warrants

Greenlane Holdings Announces Upcoming Pre-Funded Warrant Conversion and Lock-Up of Strategic Advisor Warrants

Greenlane Holdings, Inc., a Nasdaq-listed digital asset treasury company focused on the Berachain blockchain, announced that Berachain Investment Corporation will convert a portion of its pre-funded warrants into common stock while adhering to beneficial ownership limits. Additionally, strategic advisor warrant holders from the company's recent PIP…

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Aktis Oncology announced the presentation of initial clinical imaging and dosimetry data for their radioconjugate AKY-2519 targeting B7-H3 expressing solid tumors at the 2026 ASCO Annual Meeting. The company received FDA clearance to initiate a Phase 1b clinical trial of AKY-2519 mid-2026. AKY-2519 is Aktis's second clinical-stage radioconjugate de…

Toll Brothers to Acquire Private Home Builder in Northwest Arkansas

Toll Brothers to Acquire Private Home Builder in Northwest Arkansas

Toll Brothers, the US luxury homebuilder, announced a definitive agreement to acquire Buffington Homes of Arkansas, gaining a strong presence in the Fayetteville/Bentonville housing market. Buffington Homes is the largest luxury home builder in northwest Arkansas with over 1,500 lots. This acquisition supports Toll Brothers’ growth strategy, levera…

Weatherford Announces First Quarter 2026 Results

Weatherford Announces First Quarter 2026 Results

Weatherford International plc reported its first quarter 2026 results with revenues of $1,152 million, down 3% year-over-year. Operating income decreased 13% while net income increased 42% year-over-year. Despite operational disruptions due to geopolitical tensions in the Middle East, the company secured several international contracts and proposed…

Charlton Aria Acquisition Corporation Announces Receipt of Nasdaq Notice Regarding Delinquent Filing of Annual Report on Form 10-K

Charlton Aria Acquisition Corporation Announces Receipt of Nasdaq Notice Regarding Delinquent Filing of Annual Report on Form 10-K

Charlton Aria Acquisition Corporation announced receiving a Nasdaq notice for failing to timely file its Annual Report on Form 10-K for fiscal year 2025. The notice currently has no impact on trading, with the company given until June 15, 2026 to file or submit a plan for compliance. The company intends to file the report promptly to address the is…

Intuitive Announces First Quarter Earnings

Intuitive Announces First Quarter Earnings

Intuitive Surgical, Inc. (Nasdaq: ISRG) announced its first quarter 2026 financial results, highlighting a 23% revenue increase to $2.77 billion driven by growth in worldwide procedures and surgical system placements. The company saw a 17% increase in combined da Vinci and Ion procedures, with a notable 39% growth in Ion procedures. GAAP net income…

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

Ascendis Pharma A/S declared it will redeem all $575 million of its 2.25% convertible senior notes due 2028 on May 6, 2026, following the company's stock exceeding the requisite conversion price trigger. Note holders have the option to convert their notes into shares before redemption, with an increased conversion rate during the make-whole period.…

FS Bancorp, Inc. Reports First Quarter Net Income of $7.8 Million or $1.02 Per Diluted Share and Declares 53rd Consecutive Quarterly Cash Dividend

FS Bancorp, Inc. Reports First Quarter Net Income of $7.8 Million or $1.02 Per Diluted Share and Declares 53rd Consecutive Quarterly Cash Dividend

FS Bancorp, Inc. reported first quarter 2026 net income of $7.8 million or $1.02 per diluted share, a slight decrease from prior quarter and last year, driven by higher tax rates and absence of a prior quarter life insurance benefit. The company also declared its 53rd consecutive quarterly cash dividend of $0.29 per share. The report highlighted st…

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Rapport Therapeutics announced 16-week follow-up results from its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures. The data demonstrate a sustained and clinically meaningful reduction in seizures during the 8-week treatment and 8-week follow-up period, with up to 90% median seizure reduction and a half-life of approxi…